DANIEL KWIECIEN: Open Payments
NPI 1881052462 · AUBURN, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,242 in 121 payments from 15 companies in 2025. Trend: 2023 $2,673 · 2024 $3,159 · 2025 $3,242
Food & beverage: $3,233Education: $8
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $645 |
| GENZYME CORPORATION | 14 | $524 |
| Regeneron Healthcare Solutions, Inc. | 10 | $372 |
| Amgen Inc. | 10 | $316 |
| LEO Pharma Inc. | 10 | $292 |
| Janssen Biotech, Inc. | 12 | $287 |
| Galderma Laboratories, L.P. | 14 | $260 |
| PFIZER INC. | 9 | $203 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 6 | $114 |
| Novartis Pharmaceuticals Corporation | 4 | $79 |
Products named: DUPIXENT, RINVOQ, OTEZLA, TREMFYA, SKYRIZI, NEMLUVIO, CIBINQO, ANZUPGO.
Industry payments across MA — which companies pay providers there.
